Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research (Excluding Clinical Trials)

Abstract 498: Meta-analysis of genomic aberrations identified in CTCs andctDNA in triple negative breast cancer

Kellie Howard, Sharon Austin, Fang Yin Lo, Arturo Ramirez, Debbie Boles, John Pruitt, Elisabeth Mahen, Heather Collins, Amanda Leonti, Lindsey Maassel, Christopher Subia, Tuuli Saloranta, Nicole Christopherson, Kerry Deutsch, Jackie Stilwell, Eric Kaldjian, Michael Dorschner, Sibel Blau, Anthony Blau, Marcia Eisenberg, Steven Anderson and Anup Madan
Kellie Howard
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Austin
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fang Yin Lo
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arturo Ramirez
RareCyte, Inc, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debbie Boles
Laboratory Corporation of America® Holdings, Research Triangle Park, NC;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Pruitt
Laboratory Corporation of America® Holdings, Research Triangle Park, NC;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Mahen
Center for Cancer Innovation, University of Washington, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Collins
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Leonti
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsey Maassel
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Subia
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tuuli Saloranta
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Christopherson
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerry Deutsch
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jackie Stilwell
RareCyte, Inc, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Kaldjian
RareCyte, Inc, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Dorschner
Center for Cancer Innovation, University of Washington, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sibel Blau
Northwest Medical Specialties, Puyallup, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Blau
Center for Cancer Innovation, University of Washington, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcia Eisenberg
Laboratory Corporation of America® Holdings, Research Triangle Park, NC;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Anderson
Covance, Durham, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anup Madan
Covance, Seattle, WA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2016-498 Published July 2016
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA

Abstract

Technological innovation and scientific advances in understanding cancer at the molecular level have accelerated the discovery and development of both diagnostics and therapeutics. Circulating tumor cells (CTCs) and plasma circulating tumor DNA (ctDNA) are non-invasive prognostic markers that have been associated with metastatic and aggressive disease. Both CTCs and ctDNA allow molecular characterization of a tumor that is inaccessible or too risky to biopsy. The analysis of genomic aberrations in both sample types provides insights into drug resistance and can help determine appropriate, targeted cancer treatments. Mutations found in the primary or metastatic tumor can be identified in both CTCs and ctDNA as well as novel mutations that may reflect intratumoral and intermetastatic heterogeneity. When collected and evaluated over an extended period of time, changes in the CTC and/or ctDNA mutational profile can offer guidance into the effectiveness of a treatment, indicate the progression of disease, and detect recurrence of disease earlier.

We have performed whole exome sequencing of CTCs and ctDNA from a metastatic triple negative breast cancer (TNBC) patient to better understand the evolution of tumor heterogeneity during therapy. The patient was enrolled in the Intensive Trial of OMics in Cancer clinical Trial (ITOMIC-001) and initially received weekly cisplatin infusions followed by additional targeted therapy. Longitudinal peripheral blood samples were collected over a period of 272 days following enrollment in the clinical trial. CTCs were identified using the AccuCyte-CyteFinder system (RareCyte, Seattle WA).

We used next generation sequencing, and computational biology tools to analyze genomic DNA from multiple CTCs, white blood cells (WBCs) and ctDNA from various time points. We observed similar genomic aberrations in both CTCs and ctDNA that could be classified into three groups: a) a static group that remains unchanged during the course of therapy, b) a sample-specific group that is unique to each time point and c) an intermediate group that has variants that are short-lived but are present across multiple time points. Variants identified in the liquid biopsy samples were compared with variants observed in primary breast tumor, metastatic bone marrow tumor and publically available pan-cancer datasets. We then performed meta-analysis on somatic variants to identify changes in affected networks in response to therapy over time. Several key nodes were identified that could rationally have been targeted for therapy using compounds currently in clinical trials. We then compared and combined the perturbed networks obtained from the CTCs and ctDNA to better understand the etiology of TNBC. These studies represent the first step of a synergistic partnership between the genetic information obtained from the analysis of CTCs and ctDNA with innovative health care for patients with metastatic breast cancer.

Citation Format: Kellie Howard, Sharon Austin, Fang Yin Lo, Arturo Ramirez, Debbie Boles, John Pruitt, Elisabeth Mahen, Heather Collins, Amanda Leonti, Lindsey Maassel, Christopher Subia, Tuuli Saloranta, Nicole Christopherson, Kerry Deutsch, Jackie Stilwell, Eric Kaldjian, Michael Dorschner, Sibel Blau, Anthony Blau, Marcia Eisenberg, Steven Anderson, Anup Madan. Meta-analysis of genomic aberrations identified in CTCs andctDNA in triple negative breast cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 498.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 76 (14 Supplement)
July 2016
Volume 76, Issue 14 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 498: Meta-analysis of genomic aberrations identified in CTCs andctDNA in triple negative breast cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 498: Meta-analysis of genomic aberrations identified in CTCs andctDNA in triple negative breast cancer
Kellie Howard, Sharon Austin, Fang Yin Lo, Arturo Ramirez, Debbie Boles, John Pruitt, Elisabeth Mahen, Heather Collins, Amanda Leonti, Lindsey Maassel, Christopher Subia, Tuuli Saloranta, Nicole Christopherson, Kerry Deutsch, Jackie Stilwell, Eric Kaldjian, Michael Dorschner, Sibel Blau, Anthony Blau, Marcia Eisenberg, Steven Anderson and Anup Madan
Cancer Res July 15 2016 (76) (14 Supplement) 498; DOI: 10.1158/1538-7445.AM2016-498

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 498: Meta-analysis of genomic aberrations identified in CTCs andctDNA in triple negative breast cancer
Kellie Howard, Sharon Austin, Fang Yin Lo, Arturo Ramirez, Debbie Boles, John Pruitt, Elisabeth Mahen, Heather Collins, Amanda Leonti, Lindsey Maassel, Christopher Subia, Tuuli Saloranta, Nicole Christopherson, Kerry Deutsch, Jackie Stilwell, Eric Kaldjian, Michael Dorschner, Sibel Blau, Anthony Blau, Marcia Eisenberg, Steven Anderson and Anup Madan
Cancer Res July 15 2016 (76) (14 Supplement) 498; DOI: 10.1158/1538-7445.AM2016-498
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Research (Excluding Clinical Trials)

  • Abstract LB-252: Single-cell mRNA profiling reveal transcriptional heterogeneity among pancreatic circulating tumor cells
  • Abstract LB-254: Thymidylate synthase gene polymorphisms is negatively associated with gastric cancer survival
  • Abstract LB-250: Liquid biopsy in NSCLC: EpCAM+ and EpCAM- circulating tumor cells, tumor derived extracellular vesicles and cell-free circulating tumor DNA
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Circulating Biomarkers 1

  • Abstract 502: Gene expression signatures in circulating tumor cells are prognostic for metastatic lesions in breast cancer patients and correlate with response to therapy
  • Abstract 512: KRAS mutation in cell-free DNA was correlated with treatment response to gemcitabine/cisplatin chemotherapy in patients with pancreatic cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement